elismetrep (MT-8554)
/ Mitsubishi Tanabe, Kallyope
- LARVOL DELTA
Home
Next
Prev
1 to 13
Of
13
Go to page
1
December 12, 2025
CRISPR-Cas9 mediated editing of starch branching enzyme, SBE2 gene in potato for enhanced resistant starch for health benefits.
(PubMed, Front Genome Ed)
- "K301, K302, K303, K304, K305, K306, derived from distinct events, exhibited deletions and substitutions in the target exons...Furthermore, 1H-NMR study demonstrated a substantial decline in branch chain elongation in amylopectin, and thus a low degree of branching in a range of 1.15%-3.66% was reported in mutant lines, relative to the wild type (5.46%). The present study demonstrated the efficacy of CRISPR-Cas9-mediated mutagenesis of starch biosynthetic genes to develop high-amylose potato lines with elevated resistant starch content for improved health benefits."
Journal • Gene Therapies
December 08, 2025
Kallyope Announces Positive Results from Phase 2b Study of Elismetrep for the Acute Treatment of Migraine
(PharmiWeb)
- "Full data to be presented at a major medical meeting in 2026; Kallyope plans to initiate registrational studies in mid-2026...In the study, elismetrep delivered a favorable clinical profile through its novel mechanism, supporting its potential as a new therapeutic option for the large number of patients who are suffering from the debilitating effects of migraine...The performance of elismetrep across all endpoints was competitive with marketed therapies. No safety signals were observed, and the drug was well tolerated. Tolerability-related adverse events were mostly mild."
New trial • P2b data • Migraine
October 13, 2025
In silico mining of sn-1,3 regioselective Rhizomucor miehei lipase homolog with strict pH sensitivity from Cordyceps militaris.
(PubMed, Food Chem)
- "Molecular dynamic simulation revealed that the extended C-terminus (P270-K304) may endow rmCML2 with unexpected pH sensitivity by changing the H-bond network to expose the active site in pH-dependent manner. The sn-1,3 regioselectivity and pH sensitivity are expected to confer dual advantages of rmCML2 for processing lipid-related foods that require pH-dependent enzymatic conversion (e.g., cheese ripening)."
Journal
September 04, 2025
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
(clinicaltrials.gov)
- P2 | N=431 | Completed | Sponsor: Kallyope Inc. | Active, not recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ Aug 2025 | Trial primary completion date: Dec 2025 ➔ Aug 2025
Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Migraine • Pain
July 10, 2025
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
(clinicaltrials.gov)
- P2 | N=400 | Active, not recruiting | Sponsor: Kallyope Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • CNS Disorders • Migraine • Pain
March 11, 2025
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
(clinicaltrials.gov)
- P2 | N=400 | Recruiting | Sponsor: Kallyope Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • CNS Disorders • Migraine • Pain
February 27, 2025
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
(clinicaltrials.gov)
- P2 | N=400 | Not yet recruiting | Sponsor: Kallyope Inc.
New P2 trial • CNS Disorders • Migraine • Pain
November 22, 2022
Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy
(clinicaltrials.gov)
- P2 | N=156 | Completed | Sponsor: Mitsubishi Tanabe Pharma Corporation | Active, not recruiting ➔ Completed | Trial completion date: Jun 2023 ➔ Nov 2022 | Trial primary completion date: Mar 2023 ➔ Nov 2022
Trial completion • Trial completion date • Trial primary completion date • Diabetic Neuropathy • Pain • Peripheral Neuropathic Pain
September 07, 2022
Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy
(clinicaltrials.gov)
- P2 | N=144 | Active, not recruiting | Sponsor: Mitsubishi Tanabe Pharma Corporation | Recruiting ➔ Active, not recruiting
Enrollment closed • Diabetic Neuropathy • Pain • Peripheral Neuropathic Pain
December 20, 2021
Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy
(clinicaltrials.gov)
- P2; N=144; Recruiting; Sponsor: Mitsubishi Tanabe Pharma Corporation; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Diabetic Neuropathy • Pain • Peripheral Neuropathic Pain
November 17, 2021
Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy
(clinicaltrials.gov)
- P2; N=144; Not yet recruiting; Sponsor: Mitsubishi Tanabe Pharma Corporation
Clinical • New P2 trial • Diabetic Neuropathy • Pain • Peripheral Neuropathic Pain
January 31, 2020
Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms
(clinicaltrials.gov)
- P2; N=190; Completed; Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.; Active, not recruiting ➔ Completed; N=100 ➔ 190; Trial completion date: Mar 2020 ➔ Nov 2019
Clinical • Enrollment change • Trial completion • Trial completion date
May 14, 2019
Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms
(clinicaltrials.gov)
- P2; N=100; Active, not recruiting; Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.; Trial completion date: Jul 2019 ➔ Mar 2020; Trial primary completion date: Apr 2019 ➔ Dec 2019
Clinical • Trial completion date • Trial primary completion date
1 to 13
Of
13
Go to page
1